Painless NGF Compositions for Fracture Repair
Summary
The USPTO published patent application US20260097099A1 for painless nerve growth factor (NGF) compositions for bone fracture repair, filed by inventors Chelsea Bahney, Tejal Desai, Kevin Rivera, and Chengbiao Wu. The application covers pharmaceutical compositions comprising biomaterial carriers with painless NGF for stimulating bone fracture healing. Filing date was April 23, 2025.
What changed
The USPTO published patent application US20260097099A1 disclosing methods for stimulating bone fracture healing using pharmaceutical compositions comprising painless nerve growth factor (NGF) delivered via biomaterial carriers. The application claims A61K 38/185, A61K 31/727, and A61P 19/08 classifications.
For pharmaceutical companies, biotech firms, and medical researchers, this patent publication establishes prior art and signals competitive activity in the NGF-based fracture treatment space. Organizations developing bone healing therapeutics should review the claims for potential infringement concerns and Freedom to Operate implications.
What to do next
- Monitor for patent prosecution updates
- Evaluate potential licensing opportunities
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PAINLESS NGF FOR FRACTURE REPAIR
Application US20260097099A1 Kind: A1 Apr 09, 2026
Inventors
Chelsea BAHNEY, Tejal DESAI, Kevin RIVERA, Chengbiao WU
Abstract
The present disclosure is related to methods for stimulating bone fracture healing, comprising administering a pharmaceutical composition comprising biomaterial carriers comprising painless nerve growth factor (NGF).
CPC Classifications
A61K 38/185 A61K 31/727 A61P 19/08
Filing Date
2025-04-23
Application No.
19187852
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.